Lesage Anne sold $1.4M of PHVS
Lesage Anne (Chief Early Development) sold 38,472 shares of Pharvaris N.V. (PHVS) at an average of $35.37 ($35.05–$35.48, $1.36M total) across 3 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider liquidity and potential sentiment, but it does not introduce new operational or financial information about PHVS.
Market read
A $1.36M planned insider sale is unlikely to be a standalone driver, but it can slightly influence short-term sentiment and positioning.
What to watch
Traders may over-weight insider sales; the key is whether there are concurrent news catalysts (none provided here) or unusual follow-on selling beyond planned schedules.
Background
This is an SEC Form 4 insider transaction for Pharvaris N.V. (PHVS), reported by Chief Early Development Lesage Anne.
Ticker impact
Insider Lesage Anne (Chief Early Development) sold $1.36M of PHVS shares via an open-market sale under a pre-arranged 10b5-1 plan.
Likely limited/short-lived impact; any effect would be sentiment-driven rather than fundamental.
The filing is a Form 4 showing a planned sale window and weighted-average prices, but it does not include new company performance, guidance, or regulatory/clinical developments.
Market effects
Minimal; insider-sale disclosures rarely reset sector expectations without accompanying fundamentals.
None indicated; single-company Form 4 filing.
None indicated; no cross-border deal/regulatory event described.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.
Key entities
- issuerPHVS
Pharvaris N.V., the company whose shares were sold by an insider.
- insiderLesage Anne
Chief Early Development who executed open-market sales under a 10b5-1 plan.
